1. Home
  2. CICB vs SCLXW Comparison

CICB vs SCLXW Comparison

Compare CICB & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CICB

CION Investment Corporation 7.50% Notes due 2029

HOLD

Current Price

$25.16

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

N/A

Current Price

$0.15

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CICB
SCLXW
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
30
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
CICB
SCLXW
Price
$25.16
$0.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
N/A
4.0K
Earning Date
N/A
03-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
N/A
$0.18
52 Week High
N/A
$0.18

Technical Indicators

Market Signals
Indicator
CICB
SCLXW
Relative Strength Index (RSI) 39.86 43.66
Support Level $25.10 $0.10
Resistance Level $25.35 $0.16
Average True Range (ATR) 0.13 0.03
MACD -0.02 0.00
Stochastic Oscillator 20.57 54.17

Price Performance

Historical Comparison
CICB
SCLXW

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: